green
Positive treatment
Quoted verbatim 1×
4.5 score
G Cite
cited 3× by 1 distinct case ·
" Bunkley II "
Treatment trajectory · 2004 → 2026 · click a year to view as-of
2004
2015
2026
Top citers, strongest first. 4 distinct citers.
How cited ↗
discussed
Cited "see"
In Re: Opana ER Antitrust Litigation
See Valley Drug Co. v. Geneva Pharms., Inc., 344 F.3d 1294, 1306 (11th Cir. 2003) (pre-Actavis reverse payment case refusing to consider post-settlement patent ruling finding patent at issue invalid because “the reasonableness of agreements under the antitrust laws [is] to be judged at the time the agreements are entered into”), cert. denied, 543 U.S. 939 (2004); In re Cipro Cases I & II, 348 P.3d 845, 870 (Cal. 2015) (holding that justification of reverse payment “will not turn on whether the patent would ultimately have been proved valid or invalid” because “[a]greements must be as…
cited
Cited "see"
Andrx Pharmaceuticals v. Elan Corporation
See Valley Drug Co. v. Geneva Pharms., 344 F.3d 1294, 1296 (11th Cir.2003), cert. denied — U.S. —, 125 S.Ct. 308 , 160 L.Ed.2d 248 (2004).
cited
Cited "see, e.g."
Wagner v. United States
See, e.g., Wagner v. United States, 543 U.S. 939 , 125 S.Ct. 339 , 160 L.Ed.2d 247 (2004); Wagner v. United States, 543 U.S. 1018 , 125 S.Ct. 654 , 160 L.Ed.2d 493 (2004). 4 .
Retrieving the full opinion text from the archive…
Flores Molina
v.
United States
v.
United States
04-6238.
Supreme Court of the United States.
Oct 12, 2004.
Published
Citer courts: Supreme Court of Florida (1)
FLORES MOLINA
v.
UNITED STATES.
No. 04-6238.
Supreme Court of United States.
October 12, 2004.
1
C. A. 9th Cir. Certiorari denied. Reported below: 100 Fed. Appx. 689.